Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some label-supported statements are correct (indications, mechanism of action, and certain dosing concepts), but multiple claims are unsupported by the provided label excerpts and at least one is potentially contradicted/overstated relative to the label text provided.
Category Scores
Accurate Statements
REPATHA (evolocumab) is a PCSK9 inhibitor used to lower cholesterol.
Mechanism: inhibits PCSK9 binding to LDLR and lowers LDL-C (12.1); indication includes reducing LDL-C as adjunct to diet and exercise (1).
Praluent (alirocumab) is a PCSK9 inhibitor option in addition to Repatha.
Not supported or contradicted by the provided label excerpts (no comparator drug statements in supplied label text).
PCSK9 inhibitors work by inhibiting the PCSK9 protein to help the liver remove LDL cholesterol from the blood.
12.1 Mechanism of Action: inhibits PCSK9 binding to LDLR, increasing LDLRs to clear LDL from blood and lower LDL-C.
PCSK9 inhibitors work by blocking the PCSK9 protein.
12.1: inhibits binding of PCSK9 to LDLR.
Blocking PCSK9 prevents LDL cholesterol from being removed from the bloodstream and increases the number of LDL receptors on the liver.
Supported only for 'increases the number of LDLRs available to clear LDL'; the 'prevents ... removed' portion conflicts in wording (see contradictions). (12.1)
Increasing liver LDL receptors enhances cholesterol clearance.
12.1: increases LDLRs available to clear LDL from the blood thereby lowering LDL-C.
For adults in appropriate indications: either 140 mg every 2 weeks OR 420 mg once monthly administered subcutaneously.
2.1 Recommended dosage for adults with increased risk for CV events or hypercholesterolemia.
For adults and pediatric patients aged 10 years and older with HeFH: either 140 mg every 2 weeks OR 420 mg once monthly administered subcutaneously.
2.1 Recommended dosage for adults and pediatric patients aged 10 years and older with HeFH.
For HoFH: initial recommended dosage is 420 mg once monthly; can be increased to 420 mg every 2 weeks if a clinically meaningful response is not achieved in 12 weeks.
2.1 HoFH initial and dose increase criteria.
Unsupported Statements
There are no approved generic versions of Repatha on the market as of November 2023.
Not addressed in the provided REPATHA label excerpts.
Drug patent protection needs to expire before generic versions can be approved and sold.
Not addressed in the provided REPATHA label excerpts.
Generic manufacturers must demonstrate their product is bioequivalent to the brand-name drug and meet regulatory standards.
Not addressed in the provided REPATHA label excerpts.
For biologics like Repatha, the generic approval process can be more intricate than for small-molecule drugs and often involves biosimilar pathways rather than traditional generic ones.
Not addressed in the provided REPATHA label excerpts.
Statins remain a primary treatment for cholesterol lowering.
Not addressed in the provided label excerpts.
Repatha is a high-cost medication.
Not addressed in the provided REPATHA label excerpts.
Out-of-pocket cost for Repatha can vary significantly based on insurance coverage, pharmacy, and any available patient assistance programs.
Not addressed in the provided REPATHA label excerpts.
Repatha is manufactured by Amgen Inc.
Not addressed in the provided REPATHA label excerpts.
Common side effects reported for Repatha include nasopharyngitis.
The label excerpt provided for adverse reactions includes 'nasopharyngitis' as a common adverse reaction in the cardiovascular outcomes trial, but the claim is phrased as a general 'common side effects' list; still consistent, but not enough adverse-reaction listing context to confirm broad 'common side effects' wording beyond the excerpt. (6.1 excerpt supports nasopharyngitis as common in that trial; treated here as not fully verifiable across label context.)
Common side effects reported for Repatha include upper respiratory tract infection.
The label excerpt provided includes upper respiratory tract infection as a common adverse reaction in the cardiovascular outcomes trial; similar limitation in generalization (6.1).
Common side effects reported for Repatha include influenza.
Influenza is not listed in the provided adverse-reaction excerpt (6.1).
Common side effects reported for Repatha include injection site reactions.
The label excerpt provides 'Local injection site reactions' occurrence percentages, supporting injection site reactions; however the claim 'common side effects' phrasing is not explicitly tied to a 'common' threshold in the excerpt (6.1).
PCSK9 inhibitors are injectable medications designed to significantly lower LDL cholesterol levels.
While REPATHA is injectable and lowers LDL-C, the general statement about the entire class and 'significantly' is not explicitly established in the provided label excerpts.
Contradictions
High
AI Statement
Blocking PCSK9 prevents LDL cholesterol from being removed from the bloodstream and increases the number of LDL receptors on the liver.
Label Reference
12.1 states inhibition increases LDLRs available to clear LDL from the blood, thereby lowering LDL-C. (The claim's 'prevents ... removed' conflicts.)
Important Omissions
No claim was provided for evaluation regarding boxed warnings/serious hypersensitivity, latex-related warning, contraindications, or pediatric age limits; therefore those safety-critical label elements were not assessed against the user's statements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
At least one mechanistic statement directly conflicts with the label (suggesting LDL is not removed), and 'influenza' is asserted as common when not supported by the provided adverse-reaction excerpt. Other statements are non-label/background items not verifiable from the provided label text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
One statement contradicts the label mechanism wording; at least one adverse reaction claim ('influenza') is unsupported by the provided label excerpt.
Suggested Improvement
Remove/repair the contradictory mechanistic phrasing (ensure it states increased LDLR availability and LDL clearance), and only list adverse reactions that appear in the provided label excerpt (e.g., nasopharyngitis, upper respiratory tract infection, local injection site reactions; omit influenza unless supported by the exact label text).